Rigel Pharmaceuticals (RIGL)

• Market cap: $703M
• 1 day: 3.46%
• 5 days: 20.17%
• 1 month: 107.41%
• 3 months: 98.58%
• 6 months: 89.01%
• Year to date: 126.33%
• 1 year: 214.35%
• 5 years: 57.43%
• 10 years: 29.80%
• Sector: Healthcare
• Industry: Biotechnology

About: Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.

Employees: 164

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

85% more call options, than puts

Call options by funds: $643K | Put options by funds: $348K

23% more capital invested

Capital invested by funds: $203M [Q4 2024] → $250M (+$47.1M) [Q1 2025]

16% more repeat investments, than reductions

Existing positions increased: 44 | Existing positions reduced: 38

9.26% more ownership

Funds ownership: 68.59% [Q4 2024] → 77.84% (+9.26%) [Q1 2025]

10% more first-time investments, than exits

New positions opened: 23 | Existing positions closed: 21

1% more funds holding

Funds holding: 122 [Q4 2024] → 123 (+1) [Q1 2025]

0% more funds holding in top 10

Funds holding in top 10: 1 [Q4 2024] → 1 (+0) [Q1 2025]

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

• Low target: $32 18% downside
• Avg. target: $32 18% downside
• High target: $32 18% downside

1 analyst rating

• positive: 0 0%
• neutral: 1 100%
• negative: 0 0%

Cantor Fitzgerald Kristen Kluska

18% downside $32

Neutral Maintained

6 Aug 2025